Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Aviso Wealth Management

Aviso Wealth Management lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,266 shares of the medical research company’s stock after purchasing an additional 243 shares during the quarter. Aviso Wealth Management’s holdings in Amgen were worth $590,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its stake in shares of Amgen by 29.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,021 shares of the medical research company’s stock valued at $329,000 after buying an additional 231 shares during the period. Fisher Asset Management LLC boosted its holdings in Amgen by 21.3% in the third quarter. Fisher Asset Management LLC now owns 102,352 shares of the medical research company’s stock valued at $32,979,000 after acquiring an additional 17,974 shares during the last quarter. DRW Securities LLC purchased a new stake in Amgen during the third quarter valued at about $244,000. Loomis Sayles & Co. L P increased its position in Amgen by 6.6% during the 3rd quarter. Loomis Sayles & Co. L P now owns 854 shares of the medical research company’s stock worth $275,000 after purchasing an additional 53 shares in the last quarter. Finally, Qsemble Capital Management LP purchased a new position in shares of Amgen in the 3rd quarter valued at $230,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares in the company, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last ninety days. 0.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft dropped their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. UBS Group reissued a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Redburn Partners lowered their price target on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Leerink Partners decreased their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $314.04.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $306.86 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm’s 50-day moving average price is $298.92 and its two-hundred day moving average price is $298.41. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a market capitalization of $164.85 billion, a P/E ratio of 40.64, a P/E/G ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.